Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLII.a

Alveolar hemorrhage (AH), diffuse AH (DAH)

Publications

Busutti M, Cingolani A, Natali F, Mattiotti M, Grandinetti V, Baraldi O, Comai G, Candoli P, La Manna G

Everolimus-associated alveolar hemorrage relapse after drug discontinuation in a kidney transplant recipient.

Journal of nephrology 2022 Mar 14;; — 2022 Mar 14

Junpaparp P, Sharma B, Samiappan A, Rhee JH, Young KR

Everolimus-induced severe pulmonary toxicity with diffuse alveolar hemorrhage.

Annals of the American Thoracic Society 2013 Dec;10;727-9 — 2013 Dec — 727-9

Depuydt P, Nollet J, Benoit D, Praet M, Caes F

Fatal acute pulmonary injury associated with everolimus.

The Annals of pharmacotherapy 2012 Mar;46;e7 — 2012 Mar — e7

Vandewiele B, Vandecasteele SJ, Vanwalleghem L, De Vriese AS

Diffuse alveolar hemorrhage induced by everolimus.

Chest 2010 Feb;137;456-9 — 2010 Feb — 456-9